ADM Tronics Reports First Quarter of Fiscal Year 2026 Results
ADM Tronics (OTCQB:ADMT) reported strong Q1 FY2026 results with revenues reaching $973,675, marking a 13.5% increase from the same period last year. The company's electronics segment led growth with a 25% increase, while the chemical segment grew by 5%. Net income rose to $327,634 from $272,168 year-over-year.
The company continues development of its medical 厂辞苍辞迟谤辞苍庐 device for human pain treatment, planning an FDA 510(k) submission. This non-invasive therapy uses pulsed radio frequency for treating chronic and acute musculoskeletal conditions. ADMT has already launched the Vet-厂辞苍辞迟谤辞苍庐 for veterinary applications and is seeking distributors for animal markets.
ADM Tronics (OTCQB:ADMT) ha comunicato solidi risultati per il primo trimestre dell'esercizio 2026: i ricavi hanno raggiunto $973,675, con un aumento del 13,5% rispetto allo stesso periodo dell'anno precedente. Il segmento elettronico ha trainato la crescita con un incremento del 25%, mentre il segmento chimico 猫 cresciuto del 5%. L'utile netto 猫 salito a $327,634 da $272,168 su base annua.
L'azienda prosegue nello sviluppo del dispositivo medico 厂辞苍辞迟谤辞苍庐 per il trattamento del dolore nell'uomo, pianificando la presentazione di una richiesta FDA 510(k). Questa terapia non invasiva utilizza radiofrequenza pulsata per trattare condizioni muscoloscheletriche croniche e acute. ADMT ha gi脿 lanciato il Vet-厂辞苍辞迟谤辞苍庐 per applicazioni veterinarie e sta cercando distributori per i mercati animali.
ADM Tronics (OTCQB:ADMT) present贸 s贸lidos resultados del primer trimestre del ejercicio 2026, con ingresos que alcanzaron $973,675, un aumento del 13.5% respecto al mismo periodo del a帽o anterior. El segmento de electr贸nica lider贸 el crecimiento con un incremento del 25%, mientras que el segmento qu铆mico creci贸 un 5%. El ingreso neto aument贸 a $327,634 desde $272,168 interanual.
La compa帽铆a contin煤a desarrollando su dispositivo m茅dico 厂辞苍辞迟谤辞苍庐 para el tratamiento del dolor en humanos y planea presentar una solicitud FDA 510(k). Esta terapia no invasiva emplea radiofrecuencia pulsada para tratar afecciones musculoesquel茅ticas cr贸nicas y agudas. ADMT ya lanz贸 el Vet-厂辞苍辞迟谤辞苍庐 para uso veterinario y busca distribuidores para los mercados de animales.
ADM Tronics (OTCQB:ADMT)電� 2026 須岅硠鞐半弰 1攵勱赴鞐� 瓴嫟頃� 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 毵れ稖鞚� $973,675搿� 鞝勲厔 霃欔赴 雽�牍� 13.5% 歃濌皜頄堨姷雼堧嫟. 鞝勳瀽 攵�氍胳澊 25% 靹膘灔鞙茧 靹膘灔鞚� 欤茧弰頄堦碃, 頇旐暀 攵�氍胳潃 5% 靹膘灔頄堨姷雼堧嫟. 靾滌澊鞚奠潃 鞝勲厔鞚� $272,168鞐愳劀 $327,634搿� 歃濌皜頄堨姷雼堧嫟.
須岇偓電� 鞚戈皠鞚� 韱奠 旃橂毳� 鞙勴暅 鞚橂旮瓣赴 厂辞苍辞迟谤辞苍庐 臧滊皽鞚� 瓿勳啀 歆勴枆 欷戩澊氅� FDA 510(k) 鞝滌稖鞚� 瓿勴殟頃橁碃 鞛堨姷雼堧嫟. 鞚� 牍勳龚鞀奠爜 旃橂氩曥潃 毵岇劚 氚� 旮夓劚 攴缄敞瓴╆硠 歆堩櫂 旃橂鞐� 韼勳姢 霛茧敂鞓れ＜韺岇垬毳� 靷毄頃╇媹雼�. ADMT電� 鞚措 靾橃潣頃欖毄 Vet-厂辞苍辞迟谤辞苍庐鞚� 於滌嫓頄堨溂氅� 霃欕 鞁滌灔鞖� 鞙犿喌鞐呾泊毳� 彀娟碃 鞛堨姷雼堧嫟.
ADM Tronics (OTCQB:ADMT) a annonc茅 de solides r茅sultats pour le premier trimestre de l'exercice 2026, avec des revenus atteignant $973,675, soit une hausse de 13,5% par rapport 脿 la m锚me p茅riode de l'ann茅e pr茅c茅dente. Le segment 茅lectronique a port茅 la croissance avec une augmentation de 25%, tandis que le segment chimique a progress茅 de 5%. Le b茅n茅fice net est pass茅 de $272,168 脿 $327,634 en glissement annuel.
L'entreprise poursuit le d茅veloppement de son dispositif m茅dical 厂辞苍辞迟谤辞苍庐 pour le traitement de la douleur chez l'humain et pr茅voit de d茅poser une demande FDA 510(k). Cette th茅rapie non invasive utilise la radiofr茅quence puls茅e pour traiter les affections musculosquelettiques chroniques et aigu毛s. ADMT a d茅j脿 lanc茅 le Vet-厂辞苍辞迟谤辞苍庐 pour les applications v茅t茅rinaires et recherche des distributeurs pour les march茅s animaliers.
ADM Tronics (OTCQB:ADMT) meldete starke Ergebnisse f眉r Q1 des Gesch盲ftsjahres 2026: die Einnahmen beliefen sich auf $973,675, ein Anstieg von 13,5% gegen眉ber dem Vorjahreszeitraum. Das Elektroniksegment trieb das Wachstum mit einem Zuwachs von 25%, das Chemiesegment wuchs um 5%. Der Nettoertrag stieg von $272,168 auf $327,634 im Jahresvergleich.
Das Unternehmen setzt die Entwicklung seines medizinischen Ger盲ts 厂辞苍辞迟谤辞苍庐 zur Schmerzbehandlung beim Menschen fort und plant eine FDA-510(k)-Einreichung. Diese nichtinvasive Therapie nutzt gepulste Radiofrequenz zur Behandlung chronischer und akuter muskuloskelettaler Beschwerden. ADMT hat bereits das Vet-厂辞苍辞迟谤辞苍庐 f眉r veterin盲re Anwendungen eingef眉hrt und sucht Vertriebspartner f眉r den Tiermarkt.
- Revenue increased by 13.5% to $973,675 year-over-year
- Electronics segment showed strong 25% revenue growth
- Chemical segment revenue grew by 5%
- Net income increased to $327,634 from $272,168 year-over-year
- Other income doubled to $219,900 from $108,387
- Engineering segment revenue declined by 2%
- Income from operations decreased to $109,234 from $164,281
- Gross profit declined to $481,293 from $520,903
- Operating expenses increased to $372,059 from $356,622
NORTHVALE, NJ / / August 19, 2025 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its first fiscal quarter ended June 30, 2025 of Fiscal Year 2025.
The upward trend in revenues, as reported in the Company's Annual 10-K Report for the fiscal year ended March 31, 2025, continues for this first fiscal quarter ended June 30, 2025 of the fiscal year ended March 31, 2026, ADMT had an increase of over
During the quarter ended June 30, 2025, ADMT continued research and development efforts on the medical version of the Sonotron庐 for use on humans where the need for effective pain treatment without the use of drugs or opioids is very large and unmet. As previously reported, this non-invasive therapy technology utilizes pulsed radio frequency output for the treatment of chronic and acute musculoskeletal pain conditions such as osteoarthritis, tendonitis, and other conditions and diseases. The company plans on pursuing a 510(k) submission to the FDA when development of the human medical version is completed. The Company commercially introduced the Vet-Sonotron庐, a professional veterinary version of this technology for treatment of animals, and continues to seek national or regional distributors for sales and marketing to the small animal and equine veterinary markets.
Revenues for the quarter ended June 30, 2025, were
Financial Highlights
Three Months Ended | Three Months Ended | |||||||
June 30, 2025 | June 30, 2024 | |||||||
Net Revenues | $ | 973,675 | $ | 857,845 | ||||
Cost of sales | 492,382 | 336,942 | ||||||
Gross Profit | 481,293 | 520,903 | ||||||
Operating expenses: | ||||||||
Research and development | 125,589 | 127,993 | ||||||
Selling, general and administrative | 246,470 | 228,629 | ||||||
Total operating expenses | 372,059 | 356,622 | ||||||
Income from operations | 109,234 | 164,281 | ||||||
Total other income | 219,900 | 108,387 | ||||||
Income before provision for taxes | 329,134 | 272,668 | ||||||
Total provision for income taxes | 1,500 | 500 | ||||||
Net income | $ | 327,634 | $ | 272,168 | ||||
Basic and diluted earnings (loss) per common share | $ | 0.00 | $ | 0.00 | ||||
Weighted average shares of common stock outstanding - basic and diluted | 67,588,492 | 67,588,492 | ||||||
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, and FDA-Registered medical device manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at
ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at .
To receive ADMT email updates, complete form at
Sonotron庐 is a registered trademark of ADM Tronics Unlimited, Inc.
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
Contact: Andre' DiMino 201-767-6040, [email protected]
SOURCE: ADM Tronics Unlimited Inc.
View the original on ACCESS Newswire
FAQ
What were ADMT's Q1 FY2026 revenue and earnings results?
How did ADMT's different business segments perform in Q1 2026?
What is the status of ADMT's Sonotron medical device development?
What was ADMT's operating income for Q1 FY2026?
How much did ADMT's operating expenses increase in Q1 2026?
